恒瑞医药：子公司注射用SHR-A2102获得《药物临床试验批准通知书》

Core Viewpoint - Heng Rui Medicine has received approval for clinical trials of SHR-A2102, indicating progress in its drug development pipeline [1] Group 1: Company Developments - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., and Shanghai Heng Rui Medicine Co., Ltd. have obtained the clinical trial approval notice from the National Medical Products Administration for SHR-A2102 [1] - The company plans to commence clinical trials in the near future [1] Group 2: Financial Overview - For the year 2024, Heng Rui Medicine's revenue composition is projected to be 89.37% from the pharmaceutical manufacturing sector and 10.63% from other businesses [1] - As of the report date, Heng Rui Medicine's market capitalization stands at 444.6 billion yuan [1]